Cancer diagnosis from circulating nucleic acids: Review Kanda Dolaşan Nükleik Asitten Kanser Tanisi
Turkiye Klinikleri Journal of Medical Sciences, cilt.29, sa.2, ss.488-491, 2009 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 29 Sayı: 2
- Basım Tarihi: 2009
- Dergi Adı: Turkiye Klinikleri Journal of Medical Sciences
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.488-491
- Anahtar Kelimeler: Blood, Mutation, Neoplasms, Nucleic acid
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
The existence of extracellular nucleic acids in the circulation (in plasma and serum) has been known for 50 years. Today, circulating cell-free nucleic acid analysis has been studied in many clinical scenarios, such as cancer detection and prenatal diagnosis. Here, the different approaches and the technical challenges of using cell-free nucleic acids for the detection and monitoring of cancers were discussed. Finding special tumor-associated mutations, microsatellite alterations, virus associated nucleic acids or aberrant methylation of tumor supressor genes can be diagnostic criteria in cancer patients by using recent molecular techniques. Analysis of tumour-derived nucleic acids were shown to be useful for the detection and monitoring of cancers as well as for prognosis. Many such tests were shown to be rhobust enough for clinical utilization. In one study, the detection of tumor-associated aberrant p16 methylation in the circulation of patients with hepatocellular carcinoma represented the usefulness of circulating liver tumor DNA in the detection of cancer diagnosis. Epstein-Barr virus (EBV) DNA was also detectable in the serum of some patients with EBV related nasopharyngeal carcinoma, represented tumor DNA, and might have clinical implications in the clinical diagnosis. New molecular techniques will be used increasingly in circulating nucleic acid analysis for the clinical management of cancers in the future. Copyright © 2009 by Türkiye Klinikleri.